Refractory Tumor clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
San Diego, California and other locations